CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Erdafitinib

厄达替尼 杂质对照品Erdafitinib Impurities

27 个杂质条目27 impurity entries

本页汇总 厄达替尼 的 27 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 27 impurity reference standards of Erdafitinib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 厄达替尼(Erdafitinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsHPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2021 · Elawady T et al.  ·  PMID 33752054  ·  DOI
  2. 分析方法Analytical MethodsThe Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
    Frontiers in pharmacology · 2021 · Ruan LH et al.  ·  PMID 34912218  ·  DOI
  3. 分析方法Analytical MethodsPreclinical Pharmacokinetics of Erdafitinib, an FGFR Tyrosine Kinase Inhibitor, via LC-MS/MS in Sprague Dawley Rats
    Rapid communications in mass spectrometry : RCM · 2026 · Boggavarapu RK, Chimakurthy J  ·  PMID 42187041  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisA Streamlined, Green, and Sustainable Synthesis of the Anticancer Agent Erdafitinib
    Organic letters · 2023 · Singhania V et al.  ·  PMID 37278485  ·  DOI

厄达替尼 —— 原料药与杂质对照品Erdafitinib — drug substance & impurities

共 28 个条目(含原料药本体)28 items incl. the drug substance
Erdafitinib structure
原料药 APIAPI
厄达替尼Erdafitinib
Erdafitinib
CAS No.1346242-81-6
Chemical FormulaC25H30N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 1 structure
1
厄达替尼杂质1Erdafitinib Impurity 1
Erdafitinib Impurity 1
CAS No.1431869-78-1
Chemical FormulaC24H29N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 2 structure
2
厄达替尼杂质2Erdafitinib Impurity 2
Erdafitinib Impurity 2
CAS No.1346248-55-2
Chemical FormulaC25H29N5O3
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 3 structure
3
厄达替尼杂质3Erdafitinib Impurity 3
Erdafitinib Impurity 3
CAS No.1380311-71-6
Chemical FormulaC26H31N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 4 structure
4
厄达替尼杂质4Erdafitinib Impurity 4
Erdafitinib Impurity 4
CAS No.1380311-72-7
Chemical FormulaC26H31N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 8 structure
8
厄达替尼杂质8Erdafitinib Impurity 8
Erdafitinib Impurity 8
CAS No.123342-12-1
Chemical FormulaC8H4Br2N2O
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 10 structure
10
厄达替尼杂质10Erdafitinib Impurity 10
Erdafitinib Impurity 10
CAS No.55687-34-8
Chemical FormulaC8H5BrN2O
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 11 structure
11
厄达替尼杂质11Erdafitinib Impurity 11
Erdafitinib Impurity 11
CAS No.380639-03-2
Chemical FormulaC8H4Br2N2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 12 structure
12
厄达替尼杂质12Erdafitinib Impurity 12
Erdafitinib Impurity 12
CAS No.1092563-82-0
Chemical FormulaC8H5BrN2O
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 13 structure
13
厄达替尼杂质13Erdafitinib Impurity 13
Erdafitinib Impurity 13
CAS No.183801-93-6
Chemical FormulaC8H5BrN2O
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 14 structure
14
厄达替尼杂质14Erdafitinib Impurity 14
Erdafitinib Impurity 14
CAS No.55687-02-0
Chemical FormulaC8H4BrClN2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 15 structure
15
厄达替尼杂质15Erdafitinib Impurity 15
Erdafitinib Impurity 15
CAS No.2731009-66-6
Chemical FormulaC8H3Br2ClN2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 16 structure
16
厄达替尼杂质16Erdafitinib Impurity 16
Erdafitinib Impurity 16
CAS No.175858-10-3
Chemical FormulaC8H4Br2N2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 17 structure
17
厄达替尼杂质17Erdafitinib Impurity 17
Erdafitinib Impurity 17
CAS No.1448-87-9
Chemical FormulaC8H5ClN2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 18 structure
18
厄达替尼杂质18Erdafitinib Impurity 18
Erdafitinib Impurity 18
CAS No.40534-39-2
Chemical FormulaC8H10N4
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 19 structure
19
厄达替尼杂质19Erdafitinib Impurity 19
Erdafitinib Impurity 19
CAS No.1811508-63-0
Chemical FormulaC26H30N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 24 structure
24
厄达替尼杂质24Erdafitinib Impurity 24
Erdafitinib Impurity 24
CAS No.1346244-83-4
Chemical FormulaC22H24N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 27 structure
27
厄达替尼杂质27Erdafitinib Impurity 27
Erdafitinib Impurity 27
CAS No.1346243-54-6
Chemical FormulaC24H28N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 28 structure
28
厄达替尼杂质28Erdafitinib Impurity 28
Erdafitinib Impurity 28
CAS No.2839751-66-3
Chemical FormulaC10H14ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 29 structure
29
厄达替尼杂质29Erdafitinib Impurity 29
Erdafitinib Impurity 29
CAS No.16147-07-2
Chemical FormulaC8H9NO4
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 30 structure
30
厄达替尼杂质30Erdafitinib Impurity 30
Erdafitinib Impurity 30
CAS No.1346252-27-4
Chemical FormulaC25H30N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 36 structure
36
厄达替尼杂质36Erdafitinib Impurity 36
Erdafitinib Impurity 36
CAS No.1346244-78-7
Chemical FormulaC22H23N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 40 structure
40
厄达替尼杂质40Erdafitinib Impurity 40
Erdafitinib Impurity 40
CAS No.1274892-23-7
Chemical FormulaC8H5BrN2O
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 45 structure
45
厄达替尼杂质45Erdafitinib Impurity 45
Erdafitinib Impurity 45
CAS No.1021002-43-6
Chemical FormulaC10H15NO3
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 46 structure
46
厄达替尼杂质46Erdafitinib Impurity 46
Erdafitinib Impurity 46
CAS No.2504933-33-7
Chemical FormulaC13H22N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 47 structure
47
厄达替尼杂质47Erdafitinib Impurity 47
Erdafitinib Impurity 47
CAS No.226419-21-2
Chemical FormulaC8H10ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 48 structure
48
厄达替尼杂质48Erdafitinib Impurity 48
Erdafitinib Impurity 48
CAS No.75996-26-8
Chemical FormulaC9H9N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Erdafitinib Impurity 49 structure
49
厄达替尼杂质49Erdafitinib Impurity 49
Erdafitinib Impurity 49
CAS No.2735-04-8
Chemical FormulaC8H11NO2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

厄达替尼 —— 研究文献与合成路线Erdafitinib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 厄达替尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Erdafitinib. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Design and synthesis of an erdafitinib-based selective FGFR2 degrader
    Jin Y, Wang S, Pan S, et al. · Beilstein journal of organic chemistry · 2026

合成路线文献Synthetic-route papers

  1. Design and synthesis of an erdafitinib-based selective FGFR2 degrader
    Jin Y, Wang S, Pan S, et al. · Beilstein journal of organic chemistry · 2026
  2. A Streamlined, Green, and Sustainable Synthesis of the Anticancer Agent Erdafitinib
    Singhania V, Nelson CB, Reamey M, et al. · Organic letters · 2023

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

厄达替尼 杂质谱研究要点Erdafitinib — impurity profiling notes

下面这些是拿到 厄达替尼 的 28 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 28 impurity entries for Erdafitinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances